Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vitro

Currently viewing:

Administrative data

Endpoint:
in vitro gene mutation study in bacteria
Remarks:
Type of genotoxicity: gene mutation
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2002-03-29 to 2002-05-13
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2002
Report date:
2002

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
Deviations:
no
GLP compliance:
yes
Type of assay:
bacterial reverse mutation assay

Test material

Constituent 1
Chemical structure
Reference substance name:
2-butyloctanoic acid
EC Number:
248-570-1
EC Name:
2-butyloctanoic acid
Cas Number:
27610-92-0
Molecular formula:
C12H24O2
IUPAC Name:
2-butyloctanoic acid
Test material form:
liquid
Details on test material:
- Name of test material: 2-butyl octanoic acid
- Molecular formula: C12H24O2
- Molecular weight: 200.32 g/mole
- Smiles notation: O=C(O)C(CCCCCC)CCCC

Method

Details on test system and experimental conditions:
SYSTEM OF TESTING
- Species/cell type: Salmonella typhimurium strains TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Deficiencies/Proficiencies: histidine auxotroph
- Metabolic activation system: rat liver S9 of Phenobarbital/beta-Naphthoflavone induced male Sprague-Dawley rats
ADMINISTRATION:
- Dosing:
experiment I:
313, 625, 1250, 2500 and 5000 µg/plate (TA 1535, TA 98 and TA 1537 only with metabolic activation)78.1, 156, 313, 625, 1250, 2500 µg/plate (TA 102, TA 100 and TA1537 only without metabolic activation)
experiment II:
156, 313, 625, 1250, 2500 and 5000 µg/plate (TA 1535 and TA 1537 only with metabolic activation)
78.1, 156, 313, 625, 1250, 2500 µg/plate (TA 100 and TA1537 only without metabolic activation)
313, 625, 1250, 2500 and 5000 µg/plate (TA 98)
78.1, 156, 313, 625, 1250 µg/plate (TA 102)
experiment III:
9.77, 19.5, 39.1, 78.1, 156 µg/plate (TA 1535, TA 100 and TA 1537 only with metabolic activation)
4.88, 9.77, 19.5, 39.1, 78.1 µg/plate (Ta 102 and TA 1537 only without metabolic activation)
19.5, 39.1, 78.1, 156, 313 µg/plate (TA 98)
- Number of replicates: 3
- Application:
Experiment I (plate-incorporation method): Bacteria cultures, test item, S9 mix or phosphate buffer were added to the molten overlay agar and vortexed. The mixture was poured onto the surface of a medium agar plate and allowed to solidify prior to incubation. Plates were incubated upside down for approx. 72 hours at 37° C.
Experiment II and III (pre-incubation method): Bacteria cultures, test item, S9 mix or phosphate buffer were mixed and placed at 37° C for 30 minutes. Afterwards overlay agar was added and the mixture was vortexed and poured onto the surface of a medium agar plate and allowed to solidify. Plates were incubated upside down for approx. 72 hours at 37° C.
- Positive control: without metabolic activation: Sodium azide (1 µg/plate with TA 1535 and TA 100), 9-aminoacridine (50 µg/plate with TA 1537), 2-nitrofluorene (2 µl/plate with TA 98), cumene hydroperoxide (100 µg/plate with TA 102); with metabolic activation: with metabolic activation: 2-aminoanthacene (1 µg/plate with TA 1535, Ta 1537, TA 98 and TA 100; 10 µg/plate with TA 102)
- Negative control: solvent control (DMSO) and untreated control
- Pre-incubation time: 30 minutes (only in experiment II and III)
DESCRIPTION OF FOLLOW UP REPEAT STUDY: see above
Evaluation criteria:
The test item is considered as a mutagen if at least a two-fold increases in mean revertant numbers are observed at two consecutive dose-levels or at the highest practicable dose level only. In addition there must be evidence of a dose-response relationship showing increasing numbers of mutant colonies with increasing dose-levels.

Results and discussion

Test resultsopen allclose all
Key result
Species / strain:
S. typhimurium TA 100
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Remarks:
toxicity was observed at higher dose-levels with all tester strains, both in the absence and presence of S9 metabolic activation
Key result
Species / strain:
S. typhimurium TA 98
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Key result
Species / strain:
S. typhimurium TA 1537
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Remarks:
toxicity was observed at higher dose-levels with all tester strains, both in the absence and presence of S9 metabolic activation
Key result
Species / strain:
S. typhimurium TA 1535
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Remarks:
toxicity was observed at higher dose-levels with all tester strains, both in the absence and presence of S9 metabolic activation
Vehicle controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 102
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
toxicity was observed at higher dose-levels, both in the absence and presence of S9 metabolic activation
Vehicle controls validity:
valid
Positive controls validity:
valid

Applicant's summary and conclusion

Conclusions:
Interpretation of results:
negative

The test item ISOCARB 12 does not induce reverse mutation in Salmonella typhimurium under the reported experimental conditions.